ProQR Therapeutics (PRQR) Income from Continuing Operations (2013 - 2025)

ProQR Therapeutics (PRQR) has 13 years of Income from Continuing Operations data on file, last reported at 11710277.76 in Q4 2025.

• For the quarter ending Q4 2025, Income from Continuing Operations fell 33.95% year-over-year to 11710277.76; the trailing twelve-month figure through Dec 2025 stood at 48924227.85 (down 67.04% YoY), and the FY2025 full-year result was 50389115.66, down 74.43% from the prior year.
• Income from Continuing Operations advanced to 11710277.76 in Q4 2025, from 12866620.34 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 3329736.39 in Q2 2024 to a low of 23357683.12 in Q3 2022.
• A 5-year average of 12438720.11 and a median of 12288449.05 in 2025 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations tumbled 317.56% in 2021 and soared 74.36% in 2023, its largest moves.
• Tracing PRQR's Income from Continuing Operations over 5 years: stood at 20815695.43 in 2021, then surged by 37.23% to 13065287.76 in 2022, then soared by 45.33% to 7143165.06 in 2023, then retreated by 22.39% to 8742178.97 in 2024, then slumped by 33.95% to 11710277.76 in 2025.
• Business Quant data shows PRQR's Income from Continuing Operations at 11710277.76 in Q4 2025, 12866620.34 in Q3 2025, and 13745386.49 in Q2 2025.